HilleVax Inc HLVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
HilleVax Announces Reduction in Force
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
Trading Information
- Previous Close Price
- $1.75
- Day Range
- $1.75–1.81
- 52-Week Range
- $1.55–20.22
- Bid/Ask
- $1.76 / $1.80
- Market Cap
- $88.12 Mil
- Volume/Avg
- 119,254 / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 90
- Website
- https://www.hillevax.com
Comparables
Valuation
|
Metric
|
HLVX
|
EWTX
|
02509
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.42 | 5.21 | 32.68 |
Price/Sales | — | — | 100.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
HLVX
EWTX
02509
Financial Strength
|
Metric
|
HLVX
|
EWTX
|
02509
|
|---|---|---|---|
Quick Ratio | 4.98 | 29.79 | 1.70 |
Current Ratio | 5.14 | 30.24 | 1.86 |
Interest Coverage | −55.76 | — | −18.42 |
Quick Ratio
HLVX
EWTX
02509
Profitability
|
Metric
|
HLVX
|
EWTX
|
02509
|
|---|---|---|---|
Return on Assets (Normalized) | −35.79% | −23.23% | −47.40% |
Return on Equity (Normalized) | −46.36% | −24.43% | −341.08% |
Return on Invested Capital (Normalized) | −40.41% | −29.19% | −56.34% |
Return on Assets
HLVX
EWTX
02509
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zqlyhlbghx | Vlvdb | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tsrrhkcmj | Qnbhyr | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yxxfkwplh | Wwrms | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dwcjckjtn | Klyfgyr | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Tsysdswh | Hhwfx | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kxhfyyb | Lbrmd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Hzdzwgppq | Kdx | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xhsblhjqv | Zktzh | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tbqxxswyd | Bspqmq | $13.2 Bil | |||
| Incyte Corp
INCY
| Rlsgvyxqh | Vynvdtf | $13.0 Bil |
United States